Skip to Content

COVID-19 is an emerging, rapidly evolving situation.

What people with cancer should know: https://www.cancer.gov/coronavirus

Guidance for cancer researchers: https://www.cancer.gov/coronavirus-researchers

Get the latest public health information from CDC: https://www.coronavirus.gov

Get the latest research information from NIH: https://www.nih.gov/coronavirus

Radiation Research Program
Contact NExT
Show menu
Search this site
Last Updated: 09/30/20

Radiation Research Program (RRP)/Small Business Innovation Research (SBIR) Collaborations

SBIR/STRR Funding Opportunities

For current SBIR contract solicitations expiring on Oct. 26, 2020 please click here.

Topics 415, Applicator-Compatible Electronic Brachytherapy Sources for Cancer Radiotherapy, and 421, Quantitative Biomimetic Phantoms for Cancer Imaging and Radiation Dosimetry are of high interest to the Radiation Research Program. Besides these contract solicitations, support is also provided to small business innovation research in radiation oncology and related research through Omnibus Solicitations.

For current omnibus solicitations, with standard receipt dates of September 8, 2020; January 5, 2021; April 5, 2021, please click here.

The Radiation Research Program collaborates with NCI’s Small Business Innovation Research (SBIR) Development Center to provide funding to for-profit small businesses to support American entrepreneurs, translate, and commercialize laboratory science in radiation oncology and related research through SBIR/STTR grants and SBIR contracts.

RRP Program Directors work closely with SBIR Program Directors, assist in areas for development in radiation oncology, advising potential applicants, and monitoring progress of awardees. RRP-SBIR funded projects include both grants and contracts. Since the establishment of this collaboration, RRP has helped develop several requests for proposals to address specific research, development, and clinical needs in radiation oncology. Targeted contract solicitations include, but are not limited to, development of radiation-effect modulators, targeted radionuclide therapies, radiation biomarkers, radiation immune modulators, sensing tools to measure response to therapy, locally activate or release systemically delivered therapeutics, artificial intelligence tools to improve treatment planning, and mobile application for the surveillance of post-treatment quality-of-life. A list of all contract topics funded through this collaboration since 2013 is provided here. Details of SBIR awards can be found in NIH RePORTER which allows users to perform customized search of the repository of NIH-funded research projects, and access publications and patents resulting from NIH funding.

SBIR funding has become a critical resource in NCI-funded radiation oncology research, its translation, application to clinical cancer care and commercialization. This collaboration has strengthened academic — small business relationships in radiation oncology and accelerated clinical translation of grants in RRP’s portfolio. Examples of successes from this collaboration are listed below:

Collaborative Publications

Prasanna PGS, Narayanan D, Hallet K, Bernard EJ, Ahmed MM, Evans G, Vikram B, Weingarten, M and Coleman CN. Radioprotectors and radiomitigators for improving radiation therapy: The small business innovation research (SBIR) gateway for accelerating clinical translation. Radiat. Res. 184:235-238 (2015).

Zakeri K, Narayanan D, Capala J, Prasanna PGS, Buchsbaum JC, Evans G, Weingarten M, Coleman CN and Vikram B. Current status of radiation oncology research funded through the National Cancer Institute’s Small Business Innovation Program. Int. J. Radiat. Oncol. Biol. Phys. 102: e430-431 (2018)

Zakeri K, Narayanan D, Evans G, Prasanna PGS, Buchsbaum JC, Vikram B and Capala J. Advancing targeted radionuclide therapy through the National Cancer Institute’s Small Business Research Innovation Pathway. J. Nucl. Med. 60: 41-49 (2019).

Zakeri K, Narayanan D, Vikram B, Evans G, Coleman CN and Prasanna PGS. Decreasing the toxicity of radiation therapy: Radioprotectors and radiomitigators being developed by the National Cancer Institute through Small Business Innovation Research Contracts. Int. J. Radiat. Oncol. Biol. Phys. 104: 188-196 (2019).

Prasanna PGS, Narayan D, Zhang K, Rahbar A, Coleman CN and Vikram B. Radiation biomarkers: Can small businesses drive accurate radiation precision medicine? Radiat. Res. 193: 199-208 (2020)

Zakeri K, Narayan D, Prasanna PGS, Vikram B and Buchsbaum JC. Development of novel radiosensitizers through the National Cancer Institute’s Small Business Innovation Research Program. Radiat. Res. 193: 425-434 (2020).

RRP Point-of-Contact:

Pataje G Prasanna, Ph.D.
Program Director
Tel: 240-276-5690
E-mail: Pat.Prasanna@nih.gov

Molecular Radiation Therapeutics Branch